Zejula™ (niraparib) – New orphan drug approval
March 27, 2017 – The FDA announced the approval of Tesaro’s Zejula (niraparib) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Top